Drug Profile

TAK 686

Alternative Names: TAK-686

Latest Information Update: 29 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sangamo Therapeutics
Developer Sangamo Therapeutics; Takeda
Class Gene therapies; Transcription factors; Zinc finger DNA binding proteins
Mechanism of Action Gene expression regulation modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

29 Feb 2024 TAK 686 is still in preclinical development for Huntington's-disease in USA (Parenteral) (Sangamo Therapeutics Pipeline, February 2024)
28 Oct 2023 No recent reports of development identified for preclinical development in Huntington's-disease in USA (Parenteral)
23 Mar 2020 Sangamo Biosciences is now called Sangamo Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com